Results 1 to 10 of about 5,019 (231)

Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer [PDF]

Frontiers in Immunology
BackgroundOne of the main hurdles in solid tumors to the limited response of immunotherapy is the lack of sufficient T-cell infiltrate. This study aims to construct an iRGD-modified BiTE-directed T-cell therapeutic approach to enhance the treatment ...
Lu Zou, Lu Zou, Jingjing Chen, Jingjing Chen, Xinyuan Bai, Xinyuan Bai, Yingxin Wang, Yingxin Wang, Changchang Lu, Qiaoli Wang, Subiyinuer Tuerhong, Subiyinuer Tuerhong, Mengzhu Li, Qinghua Zheng, Fanyan Meng, Fanyan Meng, Fanyan Meng, Juan Du, Juan Du   +18 more
doaj   +4 more sources

Cardiovascular toxicities associated with bispecific T-cell engager therapy [PDF]

Journal for ImmunoTherapy of Cancer
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated ...
Ahmed Sayed, Malak Munir, Eric H Yang, Daniel Addison, Sarah Khan, Jiwon Kim, Syed Mahmood, Narendranath Epperla, Alexa Meara, Sanam M Ghazi, Mussammat Ferdousi, Satyam Krishan, Adnan Shaaban, Alma Habib, Onaopepo Kola-Kehinde, Patrick Ruz, Sneha Sharma, Stephanie Feldman   +17 more
doaj   +6 more sources

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

OncoImmunology, 2021
Novel therapies are needed for effective treatment of AML. In the relapsed setting, prognosis is very poor despite salvage treatment with chemotherapy. Evidence suggests that leukemic stem cells (LSCs) cause relapse.
Hélène Bonnevaux, Stephane Guerif, Jana Albrecht, Erwan Jouannot, Thibaud De Gallier, Christian Beil, Christian Lange, Wulf Dirk Leuschner, Marion Schneider, Cendrine Lemoine, Anne Caron, Céline Amara, Cédric Barrière, Justine Siavellis, Valérie Bardet, Ernesto Luna, Pankaj Agrawal, Donald R. Drake, Ercole Rao, Peter Wonerow, Chantal Carrez, Véronique Blanc, Karl Hsu, Dmitri Wiederschain, Paula G. Fraenkel, Angéla Virone-Oddos   +25 more
doaj   +2 more sources

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer [PDF]

Journal of Translational Medicine, 2023
Background Pronectins™ are a new class of fibronectin-3-domain 14th-derived (14Fn3) antibody mimics that can be engineered as bispecific T cell engager (BTCE) to redirect immune effector cells against cancer.
Caterina Riillo, Nicoletta Polerà, Maria Teresa Di Martino, Giada Juli, Craig A. Hokanson, Tatjana Odineca, Stefania Signorelli, Katia Grillone, Serena Ascrizzi, Antonia Mancuso, Nicoletta Staropoli, Basilio Caparello, Maria Cerra, Giuseppe Nisticò, Pierosandro Tagliaferri, Roberto Crea, Daniele Caracciolo, Pierfrancesco Tassone   +17 more
doaj   +2 more sources

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor

Frontiers in Immunology, 2019
Bispecific T-cell engager antibodies (BiTE) have been explored as a means to recruit cytolytic T cells to kill tumor cells. The transferrin receptor (TfR) is highly expressed on the surface of rapidly proliferating tumor cells.
Mingpeng Fu, Qi He, Zilong Guo, Xiaoran Zhou, Heli Li, Liang Zhao, Hongling Tang, Xiaoqi Zhou, Huifen Zhu, Guanxin Shen, Yong He, Ping Lei   +11 more
doaj   +3 more sources

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma [PDF]

Current Oncology
In the past few years, a new promising therapy, called bispecific T-cell engager (TCE), has been developed and is now available in many countries for patients with relapsed or refractory multiple myeloma.
Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard, Richard LeBlanc, Julie Côté, Jean-Samuel Boudreault, Dominic Duquette, Rayan Kaedbey, Marc Lalancette, Frédéric Larose, Anna Nikonova, Michel Pavic, April Shamy, Jean Roy, Michael Sebag, Sabrina Trudel, Jean-Sébastien Claveau   +16 more
doaj   +2 more sources

T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy [PDF]

Biomedicines
Antibody-based bispecific T cell engagers (TCEs) that redirect T cells to kill tumor cells have shown a promising therapeutic effect on hematologic malignancies. However, tumor-specific targeting is still a challenge for TCEs, impeding the development of
Yiming Li, Wenbin Zhao, Ying Shen, Yingchun Xu, Shuqing Chen, Liqiang Pan   +5 more
doaj   +2 more sources

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies

EMBO Molecular Medicine, 2017
Oncolytic viruses exploit the cancer cell phenotype to complete their lytic life cycle, releasing progeny virus to infect nearby cells and repeat the process.
Joshua D Freedman, Joachim Hagel, Eleanor M Scott, Ioannis Psallidas, Avinash Gupta, Laura Spiers, Paul Miller, Nikolaos Kanellakis, Rebecca Ashfield, Kerry D Fisher, Margaret R Duffy, Leonard W Seymour   +11 more
doaj   +2 more sources

Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma

PLoS ONE, 2022
Cholangiocarcinoma (CCA) is a lethal cancer of bile duct epithelial cells with a high mortality rate and limited therapeutic options. An effective treatment is, therefore, urgently needed to improve treatment outcomes for these patients. To develop a new
Thanich Sangsuwannukul, Kamonlapat Supimon, Thaweesak Chieochansin, Kornkan Choomee, Jatuporn Sujjitjoon, Mutita Junking, Pa-thai Yenchitsomanus   +6 more
doaj   +2 more sources

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins

Frontiers in Immunology, 2022
Despite the availability of an effective prophylactic vaccine, 820,000 people die annually of hepatitis B virus (HBV)-related liver disease according to WHO.
Bilge Debelec-Butuner, Bilge Debelec-Butuner, Oliver Quitt, Sophia Schreiber, Frank Momburg, Karin Wisskirchen, Karin Wisskirchen, Ulrike Protzer, Ulrike Protzer   +8 more
doaj   +1 more source